Postoperative Radiotherapy (PORT) refers to the administration of radiation therapy after surgical resection of a tumor to eliminate residual microscopic disease and reduce the risk of local recurrence.

• To improve local control by eradicating microscopic tumor remnants.
• To reduce the risk of recurrence, especially in cases with:
  • Incomplete (subtotal) resection
  • High-grade or aggressive histology
  • Positive surgical margins
  • Known radiosensitive tumors

• Typically initiated within weeks after surgery, once wound healing is adequate.
• Can be part of a multimodal treatment plan alongside chemotherapy and systemic therapies.

• High-grade gliomas
• Brain metastases (after resection)
• Meningiomas with atypical or malignant features
• Solitary fibrous tumors (SFT/HPC), especially WHO Grade II–III
• Head and neck, breast, and rectal cancers

• External Beam Radiotherapy (EBRT)
• Stereotactic Radiosurgery (SRS) or Stereotactic Radiotherapy (SRT) for focal lesions
• Dose and fractionation depend on tumor type, location, and resection extent.

• Fatigue, alopecia, dermatitis
• Cognitive effects (especially with brain irradiation)
• Radiation necrosis (rare but serious)
• Long-term endocrine or vascular effects (in specific regions)

• Adjuvant Therapy
• Gross Total Resection (GTR)
• Local Control
• Radiation Therapy